DK2262364T3 - Oxadiazoanthracenforbindelser til behandling af diabetes - Google Patents

Oxadiazoanthracenforbindelser til behandling af diabetes Download PDF

Info

Publication number
DK2262364T3
DK2262364T3 DK09718287.7T DK09718287T DK2262364T3 DK 2262364 T3 DK2262364 T3 DK 2262364T3 DK 09718287 T DK09718287 T DK 09718287T DK 2262364 T3 DK2262364 T3 DK 2262364T3
Authority
DK
Denmark
Prior art keywords
phenyl
diaza
oxo
oxa
hexahydro
Prior art date
Application number
DK09718287.7T
Other languages
English (en)
Inventor
Adnan M M Mjalli
Dharma Rao Polisetti
Thomas Scott Yokum
Mustafa Guzel
Christopher Behme
Stephen Thomas Davis
Kalpathy Santhosh
Original Assignee
Vtv Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vtv Therapeutics Llc filed Critical Vtv Therapeutics Llc
Application granted granted Critical
Publication of DK2262364T3 publication Critical patent/DK2262364T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Claims (23)

1. Forbindelse med formlen (I):
formel (I) hvor R er -(CH2)p-G1-L1-G2, hvor L1 er udvalgt fra gruppen bestående af: en direkte binding, -CH2-, -O-, -N(R16)-, -C(O)-, -CON(R16)-, -N(R16)C(0)-, -N(R16)S02-, -S02N(R16)-, -C(0)-0-, -O-C(O)-, -S-, -S(O)-, -S(0)2- og -C=C-, hvor R16 er udvalgt fra gruppen bestående af: -hydrogen, -alkyl, - aryl, -alkylen-aryl; G1 er udvalgt fra gruppen bestående af: alkynylen, arylen, heteroarylen, kondenseret arylcycloalkylen, kondenseret cycloalkylarylen, kondenseret cycloalkylheteroarylen, kondenseret heterocyclylarylen og kondenseret heterocyclylheteroarylen, hvor G1 eventuelt er substitueret 1-4 gange med substituenter uafhængigt udvalgt fra R10, hvor R10 er Rb, G2 er udvalgt fra gruppen bestående af: -aryl, -heteroaryl, -kondenseret arylcycloalkyl, -kondenseret cycloalkylaryl, -kondenseret cycloalkylheteroaryl, -kondenseret heterocyclylaryl og -kondenseret heterocyclylheteroaryl, hvor G2 eventuelt er substitueret 1-4 gange med substituenter uafhængigt udvalgt fra R11, hvor R11 er Rb, R1 er udvalgt fra gruppen bestående af: -C02H og -C02R12, hvor R12 er udvalgt fra gruppen bestående af: -Ci-io-alkyl, -cycloalkyl og -aryl, hvor R12 eventuelt er substitueret 1 -4 gange med en gruppe uafhængigt udvalgt fra Rc; R2 er udvalgt fra gruppen bestående af: -hydrogen, -alkyl, -phenyl, -cycloalkyl, -alkylen-cycloalkyl og -alkylen-phenyl, hvor alkyl-, phenyl- og cycloalkylgrupper eventuelt er substitueret 1 -4 gange med en gruppe uafhængigt udvalgt fra Rc; R3 er udvalgt fra Ra; R4 er udvalgt fra Ra; og R5 er -G3-L2-Q2-L3-G4, hvor L2 og L3 uafhængigt er udvalgt fra gruppen bestående af: en direkte binding, -CH2-, -O-, -N(R26)-, -C(O)-, -CON(R26)-, -N(R26)C(0)-, -N(R26)CON(R27)-, -N(R26)C(0)0-, -0C(0)N(R26)-, -N(R26)S02-, -S02N(R26K -C(0)-0-, -O-C(O)-, -S-, -S(O)-, -S(0)2- og -N(R26)S02N(R27)-, hvor R26 og R27 uafhængigt er udvalgt fra gruppen bestående af: hydrogen, -alkyl, -aryl og -alkylen-aryl, hvor R26 og R27 eventuelt er substitueret 1-4 gange med Rc, eller R26 og R27 er taget sammen med de atomer, hvortil de er bundet, for at danne en heterocyklisk ring på 5 til 7 dele, der indeholder 0-2 yderligere heteroatomer uafhængigt udvalgt fra oxygen, nitrogen og svovl; Q2 er udvalgt fra gruppen bestående af: en direkte binding, Ci-10-alkylen, C2-io-alkenylen og C2-io-alkynylen, G3 er udvalgt fra gruppen bestående af: -arylen, -cycloalkylen, -heterocyclylen, -heteroarylen, -kondenseret arylcycloalkylen, -kondenseret cycloalkylarylen, kondenseret cycloalkylheteroarylen, -kondenseret heterocyclylarylen og -kondenseret heterocyclylheteroarylen, hvor G3 eventuelt er substitueret 1 -4 gange med substituenter uafhængigt udvalgt fra R8, hvor R8 er udvalgt fra Rb, G4 er udvalgt fra gruppen bestående af: -aryl, -cycloalkyl, -heterocyclyl, -heteroaryl, -kondenseret arylcycloalkyl, -kondenseret cycloalkylaryl, -kondenseret cycloalkylheteroaryl, -kondenseret heterocyclylaryl og -kondenseret heterocyclylheteroaryl, hvor G4 eventuelt er substitueret 1 -4 gange med substituenter uafhængigt udvalgt fra R9, hvor R9 er udvalgt fra Rb, Ringe B og C eventuelt er substitueret 1-4 gange med substituenter uafhængigt udvalgt fra gruppen bestående af Rb; Ra er udvalgt fra gruppen bestående af: a) -hydrogen, b) -S(0)m Rd, c) -S(0)20Rd, d) -S(0)mNRdRe, e) -C(0)Rd, f) -C02Rd, g) -C(0)NRdRe, h) -haloalkyl, i) -cycloalkyl, j) -heterocyclyl, k) -Ci-io-alkyl, l) -C2-io-alkenyl, m) -C2-io-alkynyl, n) -aryl, o) -heteroaryl, P) -c l-io-alkylen-aryl, q) -C2-io-alkynylen-aryl, r) -C l-io-alkylen-heteroaryl, s) -C2-io-alkynylen-heteroaryl og t) -C(RfR8)n-aryl, hvor alkyl-, alkenyl-, alkynyl-, aryl-, heterocyclyl-, heteroaryl- og cycloalkylgrupper eventuelt er substitueret 1 -4 gange med en gruppe uafhængigt udvalgt fra Rc; Rb er udvalgt fra gruppen bestående af: a) -cycloalkyl, b) -cyan, c) -ORd, d) -N02, e) -halogen, f) -S(0)m Rd, g) -SRd, h) -S(0)20Rd, i) -S(0)mNRdRe, j) -NRdRe, k) -0(CRfR8)„NRdRe, l) -C(0)Rd, m) -C02Rd, n) -C02(CRf Rg)„CONRd Re, 0) -0C(0)Rd, p) -C(0)NRdRe, q) -NRdC(0)Re, r) -0C(0)NRdRe, s) -NRdC(0)0Re, t) -NRdC(0)NRd Re, u) -CF3, v) -OCF3, w) -haloalkyl, x) -haloalkoxy, y) -Ci-10-alkyl, z) -C2-io-alkenyl, aa) -C2-io-alkynyl, ab) -Ci-10-alkylen-aryl, ac) -Ci-io-alkylen-heteroaryl, og ad) -heteroaryl, hvor alkyl-, alkenyl-, alkynyl-, aryl- og heteroaryl- og cycloalkylgruppeme eventuelt er substitueret 1 -4 gange med en gruppe uafhængigt udvalgt fra Rc; Rc er udvalgt fra gruppen bestående af: a) -halogen, b) -amino, c) -carboxy, d) -cyan, e) -Ci-4-alkyl, f) -O-Ci-4-alkyl, g) -o-CF3, h) -cycloalkyl, 1) -O-cycloalkyl, j) -aryl, k) -Ci-4-alkylen-aryl, l) -hydroxy, m) -CF3, n) -haloalkyl, o) -haloalkoxy, p) -O-aryl, q) -heteroaryl, r) -heteroarylen-Ci-io-alkyl, s) -heterocyclyl, t) -C02-Ci-io-alkyl, u) -C02-Ci-io-alkyl-aryl, v) -kondenseret arylcycloalkyl, w) -alkynylen-heteroaryl, x) -alkylen-aryl, y) -alkynylen-aryl, z) -nitro, aa) -N(H)-C(0)-Ci-6-alkyl, og bb) -S-Ci-e-alkyl; Rd og Re uafhængigt er udvalgt fra gruppen bestående af: hydrogen, Ci-io-alkyl, C2 io-alkenyl, C2 io-alkynyl, cycloalkyl, -Ci-io-alkylen-cycloalkyl, aryl, heteroaryl og heterocyclyl, hvor alkyl-, alkenyl-, alkynyl-, cycloalkyl-, aryl-, heteroaryl- og heterocyclylgruppeme eventuelt er substitueret med en til fire substituenter uafhængigt udvalgt fra Rc; eller Rd og Re sammen med de atomer, hvortil de er bundet, danner en heterocyklisk ring på 5 til 7 dele, der indeholder 0-2 yderligere heteroatomer uafhængigt udvalgt fra oxygen, svovl og nitrogen og eventuelt substitueret med 1 -3 gange med Rc, Rf og Rs uafhængigt er udvalgt fra gruppen bestående af: hydrogen, Ci-io-alkyl, cycloalkyl, -Ci-io-alkylen-cycloalkyl, -carboxy og aryl, hvor alkyl-, cycloalkyl- og arylgruppeme eventuelt er substitueret med en til fire substituenter uafhængigt udvalgt fra Rc; eller Rf og R8 sammen med det carbon, hvortil de er bundet, danner en ring på 5 til 7 dele, der indeholder 0-2 heteroatomer uafhængigt udvalgt fra oxygen, svovl og nitrogen eventuelt substitueret med 1-3 gange med Rc; m er et heltal fra 1 til 2; n er et heltal fra 1 til 10 og p er et heltal fra O til 2; eller et farmaceutisk acceptabelt salt deraf.
2. Forbindelse ifølge krav 1, hvor R1 er -CO2H.
3. Forbindelse ifølge krav 1, hvor R2 er udvalgt fra gruppen bestående af: hydrogen og -Ci-10-alkyl, fortrinsvis, hvor R2 er hydrogen.
4. Forbindelse ifølge krav 1, hvor p er 1.
5. Forbindelse ifølge krav 1, hvor L1 er en direkte binding.
6. Forbindelse ifølge krav 1, R5 er -G3-L2-Q2-L3-G4, hvor L2 er udvalgt fra gruppen bestående af: -CH2-, -O-, -N(R26)- og -C(O)-, hvor R26 er udvalgt fra gruppen bestående af: hydrogen, -alkyl, - aryl og -alkylen-aryl; L3 er en direkte binding; Q2 er en Ci-10-alkylengruppe; G3 er en phenylengruppe, hvor G3 eventuelt er substitueret 1-4 gange med substituenter uafhængigt udvalgt fra R8, hvor R8 er udvalgt fra Rb; og G4 er udvalgt fra gruppen bestående af: cycloalkyl, phenyl, pyridinyl, benzothiopheneyl, benzothiazolyl, G4 eventuelt er substitueret 1 -4 gange med substituenter uafhængigt udvalgt fra R9, hvor R9 er udvalgt fra Rb.
7. Forbindelse ifølge krav 1, der har formlen (I-E)
eller et farmaceutisk acceptabelt salt deraf.
8. Forbindelse ifølge krav 1, hvor R4 er udvalgt fra gruppen bestående af -hydrogen, -Ci-6-alkyl og -C(0)-Ci.6-alkyl.
9. Forbindelse ifølge krav 1, hvor R5 er -G3 -L2 -Q2 -L3 -G4, hvor L2 er -O-, L3 er en direkte binding; Q2 er en Ci-io-alkylengruppe; G3 er en phenylengruppe og G4 er en phenylgruppe, hvor G4 er substitueret 1 -4 gange med substituenter uafhængigt udvalgt fra R9, hvor R9 er udvalgt fra Rb, og hvor G4 er substitueret med mindst én substituent udvalgt fra gruppen bestående af: a) -Ci-e-alkyl, b) -haloalkyl, c) -halogen, d) -alkoxy, e) -haloalkoxy, f) -CF3 og g) -O-CF3.
10. Forbindelse ifølge krav 1, der er: (S)-7-[(S)-l-carboxy-2-(4'-cyan-biphenyl-4-yl)-ethylcarbamoyl]-3-[4-(3,4-dichlor-benzyloxy)- phenyl]-2-oxo-l,2,3,5,7,8-hexahydro-4-oxa-l,6-diaza-anthracen-6-carboxylsyre-4-hydroxy- cyclohexylester, (S)-7-[(S)-l-carboxy-2-(4'-cyan-biphenyl-4-yl)-ethylcarbamoyl]-3-[4-(3,4-dichlor-benzyloxy)- phenyl]-2-oxo-l,2,3,5,7,8-hexahydro-4-oxa-l,6-diaza-anthracen-6-carboxylsyre3-hydroxy- cyclopentylester, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2-oxo-6-(pyridin-4-carbonyl)-2,3,5,6,7,8-hexahydro-1 //-4-oxa-l,6-diaza-anthracen-7-carbonyl]-amino}-propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2-oxo-6-(pyridin-3-carbonyl)-2,3,5,6,7,8-hexahydro- l//-4-oxa-1,6-diaza-anthracen-7-carbonyl]-amino} -propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2-oxo-6-((S)-tetrahydro-fu ran-2-carbonyl)-2,3,5,6,7,8-hexahydro-l//-4-oxa-l,6-diaza-anthraccn-7-carbonyl]-amino}-propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2-oxo-6-((R)-tetrahydro-furan-2-carbonyl)-2,3,5,6,7,8-hexahydro-l//-4-oxa-l,6-diaza-anthracen-7-carbonyl]-amino} -propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2 -oxo-6-(3 -phenyl-prop-2-ynyl)-2,3,5,6,7,8-hcxahydro-li/-4-oxa-l,6-diaza-anthracen-7-carbonyl]-amino j -propionsyre, (S)-7-[(S)-l-carboxy-2-(4'-cyan-biphenyl-4-yl)-ethylcarbamoyl]-3-[4-(3,4-dichlor-benzyloxy)- phenyl]-2-oxo-l,2,3,5,7,8-hexahydro-4-oxa-l,6-diaza-anthracen-6-carboxylsyre-isopropylester, (S)-7-[(S)-l-carboxy-2-(4'-cyan-biphenyl-4-yl)-ethylcarbamoyl]-3-[4-(3,4-dichlor-benzyloxy)- phenyl]-2-oxo-l,2,3,5,7,8-hexahydro-4-oxa-l,6-diaza-anthracen-6-carboxylsyre-isobutylester, (S)-7-[(S)-l-carboxy-2-(4'-cyan-biphenyl-4-yl)-ethylcarbamoyl]-3-[4-(3,4-dichlor-benzyloxy)- phenyl]-2-oxo-l,2,3,5,7,8-hexahydro-4-oxa-l,6-diaza-anthracen-6-carboxylsyre-2,2-dimethyl- propylester, (S)-7-[(S)-l-carboxy-2-(4'-cyan-biphenyl-4-yl)-ethylcarbamoyl]-3-[4-(3,4-dichlor-benzyloxy)- phenyl]-2-oxo-l,2,3,5,7,8-hexahydro-4-oxa-l,6-diaza-anthracen-6-carboxylsyre-tetrahydro-pyran-4- yl-ester, (S)-3-(4'-cyan-biphenyl-4-yl)-2-({(S)-6-cyclobutancarbonyl-3-[4-(3,4-dichlor-benzyloxy)-phenyl]- 2-oxo-2,3,5,6,7,8-hexahydro-li/-4-oxa-l,6-diaza-anthracen-7-carbonyl}-amino)-propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-({(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-6-isobutyryl-2-oxo- 2,3,5,6,7,8-hexahydro-17/-4-oxa-l,6-diaza-anthracen-7-carbonyl}-amino)-propionsyre, (S)-2-({(S)-6-benzensulfonyl-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hexahydro-l//-4-oxa-l ,6-diaza-anthracen-7-carbonyl}-amiiio)-3-(4'-cyan-biphenyl-4-yl)-propionsyre, (S)-2-({(S)-6-benzoyl-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2 -oxo-2,3,5,6,7,8-hcxahydro-l//-4-oxa- 1,6-diaza-anthracen-7-carbonyl} -amino)-3 -(4'-cyan-biphenyl-4-yl)-propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-({(S)-6-cyclopentancarbonyl-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hcxahydro-l //-4-oxa-l,6-diaza-aiithraccn-7-carbonyl}-amino)-propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2-oxo-6-(piperidin-l-carbonyl)-2,3,5,6,7,8-hexahydro- l//-4-oxa-l,6-diaza-anthracen-7-carbonyl]-amino}-propionsyre, (S)-7-[(S)-l-carboxy-2-(4'-cyan-biphenyl-4-yl)-ethylcarbamoyl]-3-[4-(3,4-dichlor-benzyloxy)- phenyl]-2-oxo-l,2,3,5,7,8-hexahydro-4-oxa-l,6-diaza-anthracen-6-carboxylsyre cyclopropylmethylester, (S)-7-[(S)-l-carboxy-2-(4'-cyan-biphenyl-4-yl)-ethylcarbamoyl]-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2-oxo-l,2,3,5,7,8-hexahydro-4-oxa-l,6-diaza-anthracen-6-carboxylsyre (R)-(tetrahydro-furan-3-yl)ester, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-6-(furan-2-carbonyl)-2- oxo-2,3,5,6,7,8-hexahydro-l//-4-oxa-l,6-diaza-anthraccn-7-carbonyl]-amino}-propionsyrc, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-6-(3-methyl-benzoyl)-2-oxo-2,3,5,6,7,8-hcxahydro-l //-4-oxa-l,6-diaza-anthraccn-7-carbonyl]-amino}-propionsyrc, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-6-(4-fluor-benzoyl)-2-oxo-2,3,5,6,7,8-hexahydro-l//-4-oxa-l ,6-diaza-anthraccn-7-carbonyl]-amino}-propionsyrc, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-6-(4-methoxy-benzoyl)- 2-oxo-2,3,5,6,7,8-hcxahydro-l//-4-oxa-l,6-diaza-anthraccn-7-carbonyl]-amino}-propionsyrc, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2-oxo-6-(3-trifluormcthyl-bcnzoyl)-2,3,5,6,7,8-hcxahydro-l /7-4-oxa-1,6-diaza-anthraccn-7-carbonyl]-amino}-propionsyre, (S)-3-(4 -cyan biphenyl-4-yl)-2-({(S)-6-cyclohexancarbonyl-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hexahydro-1H- 4-oxa-1,6-diaza-anthracen-7-carbonyl} -amino)-propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-6-(naphthalen-l- carbonyl)-2-oxo-2,3,5,6,7,8-hexahydro-l//-4-oxa-l,6-diaza-anthracen-7-carbonyl]-amino}- propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-6-(naphthalen-2-carbonyl)-2-oxo-2,3,5,6,7,8-hexahydro-1H- 4-oxa-1,6-diaza-anthracen-7-carbonyl] -amino} -propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2-oxo-6-(thiophen-2-carbonyl)-2,3,5,6,7,8-hexahydro- l//-4-oxa-l ,6-diaza-anthracen-7-carbonyl]-amino j -propionsyre, (S)-7-[(S)-l-carboxy-2-(4'-cyan-biphenyl-4-yl)-ethylcarbamoyl]-3-[4-(3,4-dichlor-benzyloxy)- phenyl]-2-oxo-l,2,3,5,7,8-hexahydro-4-oxa-l,6-diaza-anthracen-6-carboxylsyre-tert-butylester, (S)-3-(4'-cyan-biphenyl-4-yl)-2-({(S)-6-(2-cyclopentyl-acetyl)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hexahydro-l//-4-oxa-l,6-diaza-anthracen-7-carbonyl}-amino)-propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-6-(5-methyl-isoxazole- 3-carbonyl)-2-oxo-2,3,5,6,7,8-hexahydro-17/-4-oxa-l,6-diaza-anthracen-7-carbonyl]-amino}- propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2-oxo-6-(thiophen-2-sulfonyl)-2,3,5,6,7,8-hexahydro-1 //-4-oxa-1,6-diaza-anthraccn-7-carbonyl]-amino} -propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-({(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-6-dimethylcarbamoyl-2- oxo-2,3,5,6,7,8-hexahydro-17/-4-oxa-l,6-diaza-anthracen-7-carbonyl}-amino)-propionsyre, (S)-2-({(S)-6-benzyl-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hexahydro-l//-4-oxa- l,6-diaza-anthracen-7-carbonyl}-amino)-3-(4'-cyan-biphenyl-4-yl)-propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-({(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2-oxo-6-phenethyl- 2,3,5,6,7,8-hexahydro-l/7-4-oxa-l,6-diaza-anthracen-7-carbonyl}-amino)-propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2-oxo-6-(2,4,6-trifluor-benzoyl)-2,3,5,6,7,8-hexahydro-l//-4-oxa-1,6-diaza-anthraccn-7-carbonyl]-amino}-propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2-oxo-6-(toluen-2-sulfony 1)-2,3,5,6,7,8-hcxahydro-l//-4-oxa-l,6-diaza-anthraccn-7-carbonyl]-amino}-propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-6-(2-methyl-benzyl)-2- oxo-2,3,5,6,7,8-hexahydro-l//-4-oxa-l,6-diaza-anthracen-7-carbonyl]-amino}-propionsyrc, (S)-3-(4'-cyan-biphenyl-4-yl)-2-({(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2-oxo-6-pyridin-2- ylmcthyl-2,3,5,6,7,8-hcxahydro-l//-4-oxa-l,6-diaza-andiraccn-7-carbonyl}-amino)-propionsyrc, (S)-3-(4'-cyan-biphenyl-4-yl)-2-({(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2-oxo-6-thiophen-2- ylmcthyl-2,3,5,6,7,84icxahydro-l//-4-oxa-l,6-diaza-andiraccn-7-carbonyl}-amino)-propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(S)-3-[4-(3,4-dichlor-benzyloxy)-phcnyl]-6-(2-fluor-bcnzyl)-2-oxo-2,3,5,6,7,8-hexahydro-1H- 4-oxa-1,6-diaza-anthracen-7-carbonyl]-amino} -propionsyre, (S)-2-({(S)-6-(2-chlor-benzyl)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hexahydro-l//-4-oxa-1,6-diaza-anthracen-7-carbonyl} -amino)-3 -(4'-cyan-biphenyl-4-yl)-propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-6-(2-methoxy-benzyl)-2-oxo-2,3,5,6,7,8-hexahydro-l//-4-oxa-l,6-diaza-anthracen-7-carbonyl]-amino} -propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-6-(6-methyl-pyridin-2-ylmethyl)-2-oxo-2,3,5,6,7,8-hexahydro-l//-4-oxa-l,6-diaza-anthracen-7-carbonyl]-amino}-propionsyre, (S)-2-({(S)-6-(6-brom-pyridin-2-ylmethyl)-3-[4-(3,4-dichlor-benxyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hexahydro-l//-4-oxa-l,6-diaza-anthracen-7-carbonyl j -amino)-3-(4’-cyan-biphenyl-4-yl)-propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-({(S)-6-(5-cyan-6-methylsulfanyl-pyridin-2-ylmethyl)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hexahydro-l//-4-oxa-l,6-diaza-anthracen-7-carbonyl} -amino)-propionsyre, (S)-3-(4'-cyan-biphcnyl-4-yl)-2-1 [(S)-3-[4-(3,4-dichlor-bcnzyloxy)-phenyl]-6-(l//-imidazol-2-y 1 methyl )-2-oxo-2,3,5,6,7,8-hexahydro-l//-4-oxa-1,6-diaza-anth racen-7-carbony 1]-amino }-propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2- {[(S)-3-[4-(3,4-dichlor-bcnzyloxy)-phenyl]-6-( 1 -methyl-1H-mndazol-2-yl-methyl)-2-oxo-2,3,5,6,7,8-hexahydro-l//-4-oxa-l,6-diaza-anthracen-7-carbonyl]-amino} -propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-({(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2-oxo-6-thiazol-2- ylmethyl-2,3,5,6,7,8-hexahydro-l//-4-oxa-l,6-diaza-anthracen-7-carbonyl}-amino)-propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2-oxo-6-(pyridin-2- carbonyl)-2,3,5,6,7,8-hexahydro-l//-4-oxa-l,6-diaza-anthracen-7-carbonyl]-amino}-propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-6-(2-nitro-bcnzenesulfonyl)-2-oxo-2,3,5,6,7,8-hcxahydro-1//-4-oxa-1,6-diaza-anthracen-7-carbonyl]-amino}-propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-6-(3-nitro-bcnzenesulfonyl)-2-oxo-2,3,5,6,7,8-hexahydm- l//-4-oxa-l,6-diaza-anthracen-7-carbonyl]-amino}-propionsyre, (S)-2-({(S)-6-(2-cyan-benzyl)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hexahydro-l//-4-oxa-1,6-diaza-anthracen-7-carbonyl} -amino)-3 -(4'-cyan-biphenyl-4-yl)-propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-({(S)-6-cyclopropylmethyl-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hcxahydro-l//-4-oxa-l ,6-diaza-anthracen-7-carbonyl}-amino)-propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2 -oxo-6-(3 -pyrimidin-2- yl-prop-2-ynyl)-2,3,5,6,7,8-hexahydro-l//-4-oxa-l,6-diaza-anthracen-7-carbonyl]-amino}- propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2-oxo-6-(3-thiophen-3-yl-prop-2-ynyl)-2,3,5,6,7,8-hexahydro-l//-4 -oxa-1,6-diaza-anthracen-7 -carbonyl] -amino} -propionsyre, (S)-2-({(S)-6-benzoyl-3-[4-(2,6-dichlor-bcnzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hcxahydro-l //-4-oxa- 1.6- diaza-anthracen-7-carbonyl} -amino)-3 -(4'-cyan-biphenyl-4-yl)-propionsyre, (S )-2-( !(S)-6-bcnzoyl-3-[4-(2,5-dichlor-bcnzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hexahydro-l//-4-oxa- 1.6- diaza-anthracen-7-carbonyl}-amino)-3-(4'-cyan-biphenyl-4-yl)-propionsyre, (S)-2-({(S)-6-bcnzoyl-3-[4-(3-chloro-bcnzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hcxahydro-l//-4-oxa- 1.6- diaza-anthracen-7-carbonyl} -amino)-3 -(4'-cyan-biphenyl-4-yl)-propionsyre, (S)-2-({(S)-6-benzoyl-3-[4-(4-chlor-benzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hexahydro-l//-4-oxa-l,6- diaza-anthracen-7-carbonyl}-amino)-3-(4'-cyan-biphenyl-4-yl)-propionsyre, (S)-2-({(S)-6-benzoyl-3-[4-(4-chlor-3-trifluormethyl-benzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8- hexahyclro-l//-4-oxa-l,6-diaza-anthraccn-7-carbonyl}-amiiio)-3-(4'-cyan-bipheiiyl-4-yl)- propionsyre, (S)-2-({(S)-6-benzoyl-3-[4-(4-methoxy-3-trifluormethyl-benzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8- hexahydro-l//-4-oxa-l,6-diaza-anthraccn-7-carbonyl}-amino)-3-(4'-cyan-biphenyl-4-yl)- propionsyre, (S)-7-[(S)-l-carboxy-2-(4'-cyan-biphenyl-4-yl)-ethylcarbamoyl]-3-[4-(5,6-dichlor-pyridin-3- ylmethoxy)-phenyl]-2-oxo-l,2,3,5,7,8-hexahydro-4-oxa-l,6-diaza-anthracen-6-carboxylsyre-fert- butylester, (S)-2-({(S)-6-benzoyl-3-[4-(5,6-dichlor-pyridin-3-ylmethoxy)-phenyl]-2-oxo-2,3,5,6,7,8-hexahydro- l//-4-oxa-l,6-diaza-anthracen-7-carbonyl}-amino)-3-(4'-cyan-biphenyl-4-yl)-propionsyre, (S)-2-({(S)-6-benzyl-3-[4-(5,6-dichlor-pyridin-3-ylmethoxy)-phenyl]-2-oxo-2,3,5,6,7,8-hexahydro-17/-4-oxa-l,6-diaza-anthraccn-7-carbonyl j -amino)-3-(4'-cyan-biphenyl-4-yl)-propionsyrc, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(S)-3-[4-(5,6-dichlor-pyridin-3-ylmethoxy)-phenyl]-2-oxo-6-(thiophene-2-carbonyl)-2,3,5,6,7,8-hcxahydro-l 7/-4-oxa-l,6-diaza-anthraccn-7-carbonyl]-amino}-propionsyre, (S)-2-({(S)-3-[4-(3-chlor-benzyloxy)-phenyl]-2-oxo-6-thiazol-2-ylmethyl-2,3,5,6,7,8-hexahydro-177-4-oxa-1,6-diaza-anthracen-7-carbonyl} -amino)-3 -(4'-cyan-biphenyl-4-yl)-propionsyre, (S)-7-[(S)-l-carboxy-2-(4'-cyan-biphenyl-4-yl)-ethylcarbamoyl]-3-[4-(3,4-dichlor-benzyloxy)- phenyl]-l-methyl-2-oxo-l,2,3,5,7,8-hexahydro-4-oxa-l,6-diaza-anthracen-6-carboxylsyre- isopropylester, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-l-methyl-2-oxo-6-(3- phenyl-prop-2-ynyl)-2,3,5,6,7,8-hexahydro-l//-4-oxa-l,6-diaza-anthracen-7-carbonyl]-amino}- propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-l-methyl-2-oxo-6-(l-phenyl-pmpyl)-2,3,5,6,7,8-hcxahydro-l /7-4-oxa-1,6-diaza-anthracen-7-carbonyl]-amino }-propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-6-(2-ethyl-benzyl)-l-methyl-2-oxo-2,3,5,6,7,8-hexahydro-l//-4-oxa-l,6-diaza-anthracen-7-carbonyl]-amino}-propionsyre, (S)-3-(4 -cyan-biphenyl-4 yl)-2-{[(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-6-(2-isopropyl-benzyl)- 1- mcthyl-2-oxo-2,3,5,6,7,8-hexahydro-l//-4-oxa-l,6-diaza-anthraccn-7-carbonyl]-amino}- propionsyre, (S)-3-(4 -cyan-biphenyl-4-yl)-2-({(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-6-indan-2-yl-l-methyl- 2- oxo-2,3,5,6,7,8-hexahydro-l//-4-oxa-1,6-diaza-anthraccn-7-carbonyl}-amino)-propionsyrc, (S)-3-(4'-cyan-biphenyl-4-yl)-2-({(S)-6-cyclopentyl-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-l-methyl-2-oxo-2,3,5,6,7,8-hexahydro-l /7-4-oxa-1,6-diaza-anthraccn-7-carbonyl}-amino)-propionsyrc, (S)-3-(4'-cyan-biphenyl-4-yl)-2-({(S)-6-cyclohexyl-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-l-methyl-2- oxo-2,3,5,6,7,8-hexahydro-l/7-4-oxa-l,6-diaza-aiithraccn-7-carbonyl}-amino)-propionsyrc, (S)-3-(4'-cyan-biphenyl-4-yl)-2-({(S)-6-cyclobutyl-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-l-methyl-2-oxo-2,3,5,6,7,8-hexahydro-1//-4-oxa-l ,6-diaza-anthraccn-7-carbonyl} -amino)-propionsyrc, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-l-methyl-2-oxo-6-(l-phenyl-cyc lopcntylmcthy 1)-2,3,5,6,7,8-hcxahydro-l//-4-oxa-l,6-diaza-anthracen-7-carbonyl]-amino} -propionsyre, (S)-3-(4’-cyan-biphenyl-4-yl)-2-({(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-6-ethyl-l-methyl-2-oxo- 2.3.5.6.7.8- hcxahydro-1 /7-4-oxa-] ,6-diaza-anthraccn-7-carbonyl )-amino)-propionsyre, (S)-2-({(S)-6-(carboxy-phenyl-methyl)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-l-methyl-2-oxo- 2.3.5.6.7.8- hexahydro-17/-4-oxa-l,6-diaza-anthracen-7-carbonyl}-amino)-3-(4’-cyan-biphenyl-4-yl)-propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-l-methyl-2-oxo-6-(l- phenyl-ethyl)-2,3,5,6,7,8-hexahydro-l//-4-oxa-l,6-diaza-anthracen-7-carbonyl]-amino}- propionsyre, (S)-2-({(S)-6-(2-acetylamino-4-methyl-thiazole-5-sulfonyl)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2- oxo-2,3,5,6,7,8-hexahydro-17/-4-oxa-l,6-diaza-anthracen-7-carbonyl}-amino)-3-(4'-cyan-biphenyl- 4-yl)-propionsyre, (S)-7-((S)-2-biphenyl-4-yl-l-carboxy-ethylcarbamoyl)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2-oxo- 1.2.3.5.7.8- hcxahydro-4-oxa-l,6-diaza-anthraccn-6-carboxylsyrc-isopropylestcr, (S)-2-( i(S)-6-bcnzoyl-3-[4-(3,4-dichlor-bcnzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hcxahydro-17/-4-oxa- l,6-diaza-anthracen-7-carbonyl}-amino)-3-(4-pyridin-4-yl-phenyl)-propionsyre, (S)-2-( j(S)-6-bcnzoyl-3-[4-(3,4-dichlor-bcnzyloxy)-phcnyl]-2-oxo-2,3,5,6,7,8-hexahydro-l//-4-oxa- 1,6-diaza-anthracen-7-carbonyl} -amino)-3 -(4'-chlor-biphenyl-4-yl)-propionsyre, (S)-2-({(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2-oxo-6-pyridin-2-ylmethyl-2,3,5,6,7,8-hexahydro-1 /7-4-oxa-l,6-diaza-anthraccn-7-carbonylj -amino)-3-(4'-methyl-biphenyl-4-yl)-propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(3R,7S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-l-methyl-2-oxo-6-((S)-1 -phenyl-propyl )-2,3,5,6,7,8-hcxahydro-1 //-4-oxa-1,6-diaza-anthraccn-7-carbonyl]-aminoj -propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(3S,7S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-l-methyl-2-oxo-6-((S)-l-phcnyl-propyl)-2,3»5,6,7,8-hcxahydro-l //-4-oxa-l ,6-diaza-anthraccn-7-carbonyl]-aminoj-propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(3S,7S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-l-methyl-2-oxo-6-((R)-l-phcnyl-propyl)-2,3,5,6,7,8-hcxahydro-l //-4-oxa-l ,6-diaza-anthraccn-7-carbonyl]-amino|-propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(3R,7S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-l-methyl-2-oxo-6- ((R)-l-phenyl-propyl)-2,3,5,6,7,8-hexahydro-l//-4-oxa-l,6-diaza-anthracen-7-carbonyl]-amino}- propionsyre, (S)-3-(4'-chlor-biphenyl-4-yl)-2-{[(3R,7S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-l-methyl-2-oxo-6- ((S)-l-phenyl-propyl)-2,3,5,6,7,8-hexahydro-l//-4-oxa-l,6-diaza-anthracen-7-carbonyl]-amino}- propionsyre, (S)-2-{[(3R,7S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-l-methyl-2-oxo-6-((S)-l-phenyl-propyl)- 2.3.5.6.7.8- hexahydro-l//-4-oxa-l,6-diaza-anthracen-7-carbonyl]-amino}-3-(4'-methoxy-biphenyl-4-yl)-propionsyre, (S)-2-{[(3R,7S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-l-methyl-2-oxo-6-((S)-l-phenyl-propyl)- 2.3.5.6.7.8- hexahydro-l//-4-oxa-l,6-diaza-anthracen-7-carbonyl]-amino}-3-(4'-fluor-biphenyl-4-yl)-propionsyre, (S)-3-(4'-chlor-biphenyl-4-yl)-2-{[(3S,7S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-l-methyl-2-OXO-6- ((S)-l-phenyl-propyl)-2,3,5,6,7,8-hexahydro-l//-4-oxa-l,6-diaza-anthracen-7-carbonyl]-amino}- propionsyre, (S)-2-{[(3S,7S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-l-methyl-2-oxo-6-((S)-l-phenyl-propyl)- 2.3.5.6.7.8- hexahydro-l//-4-oxa-l,6-diaza-anthracen-7-carbonyl]-amino}-3-(4'-methoxy-biphenyl-4-yl)-propionsyre, (S)-2-{[(3S,7S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-l-methyl-2-oxo-6-((S)-l-phenyl-propyl)- 2.3.5.6.7.8- hcxahydro-l//-4-oxa-l,6-diaza-anthracen-7-carbonyl]-amino}-3-(4'-fluor-biphenyl-4-yl)-propionsyre, (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-6-(3,5-dimethyl- isoxazol-4-sulfonyl)-l-methyl-2-oxo-2,3,5,6,7,8-hexahydro-lH-4-oxa-l,6-diaza-anthracen-7- carbonyl] -amino} -propionsyre, (R) -3-(4’-cyan-biphenyl-4-yl)-2-{[(3R,7S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-l-methyl-2-oxo-6-((S)-l-phenyl-propyl)-2,3,5,6,7,8-hexahydro-lH-4 -oxa-1,6-diaza-anthracen-7 -carbonyl] -amino} -propionsyre, (S) -2-({(S)-6-benzoyl-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hexahydro-lH-4-oxa- l,6-diaza-anthracen-7-carbonyl}-amino)-3-[4-(pyridin-4-yloxy)-phenyl]-propionsyre, (S)-2-({(S)-6-(2-amino-4-methyl-thiazol-5-sulfonyl)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-l- methyl-2-oxo-2,3,5,6,7,8-hcxahydro-l//-4-oxa-l,6-diaza-anthracen-7-carbonyl}-amino)-3-(4'-cyan- biphenyl-4-yl)-propionsyre, (S)-2-({(S)-6-(2-amino-4-methyl-thiazole-5-sulfonyl)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-l-mcthyl-2-oxo-2,3,5,6,7,8-hcxahydro-1 /7-4-oxa-1,6-diaza-anthracen-7-carbonyl}-amino)-3-(4'-cyan-biphenyl-4-yl)-propionsyre, (S)-2-({(S)-6-(2-amino-4-methyl-thiazole-5-sulfonyl)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2-oxo- 2.3.5.6.7.8- hexahydro-17/-4-oxa-l,6-diaza-anthracen-7-carbonyl}-amino)-3-(4'-cyan-biphenyl-4-yl)-propionsyre, eller (S)-2-({(S)-6-(2-amino-4-methyl-thiazol-5-sulfonyl)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2-oxo- 2.3.5.6.7.8- hcxahydro-l/7-4-oxa-l,6-diaza-anthracen-7-carbonyl|-amino)-3-(4'-cyan-biphenyl-4-yl)-propionsyre, eller et farmaceutisk acceptabelt salt deraf.
11. Forbindelse ifølge krav 1, hvor forbindelsen er (S)-2-({(S)-6-benzoyl-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hcxahydro-l/7-4-oxa-l,6-diaza-anthraccn-7-carbonyl}-amino)-3-(4'-cyan-biphenyl-4-yl)-propionsyre eller et farmaceutisk acceptabelt salt deraf.
12. Forbindelse ifølge krav 1, hvor forbindelsen er (S)-3-(4'-cyan-biphenyl-4-yl)-2-({(S)-6-cyclopcntancarbonyl-3-[4-(3,4-dichlor-bcnzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hcxahydro-l//-4-oxa- l,6-diaza-anthracen-7-carbonyl}-amino)-propionsyre eller et farmaceutisk acceptabelt salt deraf.
13. Forbindelse ifølge krav 1, hvor forbindelsen er (S)-7-[(S)-l-carboxy-2-(4'-cyan-biphenyl-4-yl)-ethylcarbamoyl]-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-2-oxo-l,2,3,5,7,8-hexahydro-4-oxa-l,6-diaza-anthracen-6-carboxylsyrecyclopropylmethylester eller et farmaceutisk acceptabelt salt deraf.
14. Forbindelse ifølge krav 1, hvor forbindelsen er (S)-3-(4’-cyan-biphenyl-4-yl)-2-{[(S)-3-[4-(3,4-dichlor-bcnzyloxy)-phcnyl]-6-(furan-2-carbonyl)-2-oxo-2,3,5,6,7,8-hexahydro-l//-4-oxa-l,6-diaza-anthracen-7-carbonyl]-amino }-propionsyre eller et farmaceutisk acceptabelt salt deraf.
15. Forbindelse ifølge krav 1, hvor forbindelsen er (S)-3-(4’-cyan-biphenyl-4-yl)-2-({(S)-3-[4-(3,4-dichlor-benzyloxy-phenyl]-2-oxo-6-pyridin-2-ylmethyl-2,3,5,6,7,8-hexahydro-l//-4-oxa-l,6-diaza-anthracen-7-carbonyl}-amino)-propionsyre eller et farmaceutisk acceptabelt salt deraf.
16. Forbindelse ifølge krav 1, hvor forbindelsen er (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(3R,7S)-3-[4-(3,4-dichlor-benzyloxy)-phenyl]-l-methyl-2-oxo-6-((S)-l-phenyl-propyl)-2,3,5,6,7,8-hexahydro-l/7-4-oxa-l,6-diaza-anthracen-7-carbonyl]-amino}-propionsyre eller et farmaceutisk acceptabelt salt deraf.
17. Forbindelse ifølge krav 1, hvor forbindelsen er (S)-3-(4'-cyan-biphenyl-4-yl)-2-{[(3S,7S)-3-[4-(3,4-dichlor-benzyloxy)-phcnyl]-l -mcthyl-2-oxo-6-((S)-l -phcnyl-propyl)-2,3,5,6,7,8-hcxahydro-l /7-4-oxa-l,6-diaza-anthracen-7-carbonyl]-amino}-propionsyre eller et farmaceutisk acceptabelt salt deraf.
18. Kombination af en forbindelse ifølge et hvilket som helst af kravene 1 til 17 og et eller flere andre terapeutiske midler.
19. Farmaceutisk sammensætning, der omfatter en forbindelse som defineret ifølge et hvilket som helst af kravene 1 til 17, eller en kombination som defineret ifølge krav 18, og en farmaceutisk acceptabel bærer eller fortyndingsmiddel.
20. Forbindelse som defineret ifølge et hvilket som helst af kravene 1 til 17, en kombination som defineret ifølge krav 18, eller en sammensætning som defineret ifølge krav 19 til anvendelse som et medikament.
21. Forbindelse, kombination eller sammensætning til anvendelse ifølge krav 20 til hæmning af tarmmotilitet, sænkning af blodsukker hos et menneske, forsinkelse eller forebyggelse af progressionen fra IGT til type 2-diabetes, forsinkelse eller forebyggelse af progressionen fra ikke-insulinkrævende type 2-diabetes til insulinkrævende type 2-diabetes, forsinkelse eller forebyggelse af type 1 -diabetes, eller appetitregulering eller behandling af en forstyrrelse i energiforbrug; fortrinsvis hvor sygdommen eller lidelsen er udvalgt fra metaboliske sygdomme, glukoseintolerance, hyperglycæmi, dyslipidæmi, type 1-diabetes, type 2-diabetes, hypertriglyceridæmi, syndrom X, insulinresistens, IGT, fedme, diabetes som en følge af fedme, diabetisk dyslipidæmi, hyperlipidæmi, kardiovaskulære sygdomme, hypertension eller komplikationer stammende fra eller forbundet med diabetes.
22. Forbindelse, kombination eller sammensætning til anvendelse ifølge krav 20 til behandlingen og/eller forebyggelse af type 2-diabetes.
23. Forbindelse, kombination eller sammensætning til anvendelse ifølge krav 20 til sænkning af blodsukker hos et menneske.
DK09718287.7T 2008-03-07 2009-03-06 Oxadiazoanthracenforbindelser til behandling af diabetes DK2262364T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3459908P 2008-03-07 2008-03-07
PCT/US2009/036333 WO2009111700A2 (en) 2008-03-07 2009-03-06 Oxadiazoanthracene compounds for the treatment of diabetes

Publications (1)

Publication Number Publication Date
DK2262364T3 true DK2262364T3 (da) 2016-03-21

Family

ID=41056666

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09718287.7T DK2262364T3 (da) 2008-03-07 2009-03-06 Oxadiazoanthracenforbindelser til behandling af diabetes

Country Status (18)

Country Link
US (7) US7727983B2 (da)
EP (1) EP2262364B1 (da)
JP (1) JP5382952B2 (da)
KR (1) KR101616737B1 (da)
CN (1) CN101959405B (da)
AU (1) AU2009221722B2 (da)
BR (1) BRPI0910282A2 (da)
CA (1) CA2716664C (da)
DK (1) DK2262364T3 (da)
EA (1) EA018225B1 (da)
ES (1) ES2567451T3 (da)
HK (1) HK1148435A1 (da)
IL (1) IL207570A (da)
MA (1) MA32175B1 (da)
MX (1) MX2010009752A (da)
NZ (1) NZ587343A (da)
WO (1) WO2009111700A2 (da)
ZA (1) ZA201006367B (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA018225B1 (ru) 2008-03-07 2013-06-28 Транстек Фарма, Инк. Соединения оксадиазоантрацена для лечения диабета
DK2413693T3 (da) * 2009-03-30 2015-11-16 Vtv Therapeutics Llc Substituerede azoanthracenderivater, farmaceutiske sammensætninger og fremgangsmåder til anvendelse heraf
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
MX2013006768A (es) 2010-12-23 2013-07-22 Pfizer Moduladores de receptor de glucagon.
WO2012096824A1 (en) * 2011-01-12 2012-07-19 Transtech Pharma, Inc. Phenylglyoxylic acid derivatives and their preparation and use
IL227559A (en) 2011-02-08 2016-04-21 Pfizer Glucagon receptor modulator
KR20140023441A (ko) 2011-07-22 2014-02-26 화이자 인코포레이티드 퀴놀린일 글루카곤 수용체 조절제
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CA2868033A1 (en) * 2012-03-22 2013-09-26 Transtech Pharma, Llc Tris(hydroxymethyl)aminomethane salts of a small-molecule glp1r agonist and pharmaceutical compositions and uses thereof
WO2014064215A1 (en) 2012-10-24 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL
AU2014207748B2 (en) * 2013-01-17 2018-10-11 Vtv Therapeutics Llc Combinations of a GLP1R agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders
CN112457301A (zh) * 2014-07-25 2021-03-09 赛尔基因第二国际有限公司 新的glp-1受体调节剂
ES2805743T3 (es) 2015-03-24 2021-02-15 Inst Nat Sante Rech Med Método y composición farmacéutica para uso en el tratamiento de la diabetes
JOP20190060A1 (ar) * 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
TW201925204A (zh) * 2017-11-22 2019-07-01 日商第一三共股份有限公司 稠合三環化合物
JP2021523877A (ja) 2018-05-08 2021-09-09 ブイティーブイ・セラピューティクス・エルエルシー Ｇｌｐ１ｒアゴニストの治療的使用
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
TW202210487A (zh) * 2020-05-28 2022-03-16 中國大陸商杭州中美華東製藥有限公司 一種ｇｌｐ－１受體激動劑游離鹼的製備方法
EP4159719A1 (en) * 2020-05-28 2023-04-05 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Preparation method for (s)-2-amino-3-(4-(2,3-dimethylpyridin-4-yl)phenyl)methyl propionate diacid salt
TW202220985A (zh) 2020-09-01 2022-06-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
EP4227299A1 (en) 2020-10-12 2023-08-16 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Benzimidazolone glp-1 receptor agonist and use thereof
EP4242202A4 (en) 2020-11-27 2024-05-15 Shenzhen Salubris Pharm Co Ltd BENZIMIDAZOLE DERIVATIVE, ITS PREPARATION METHOD AND ITS MEDICAL USE
CN116940561A (zh) 2021-03-22 2023-10-24 杭州中美华东制药有限公司 噻吩类glp-1受体激动剂及其用途
JPWO2022202864A1 (da) 2021-03-24 2022-09-29
WO2022262615A1 (zh) * 2021-06-17 2022-12-22 杭州中美华东制药有限公司 蒽类化合物、其制备方法和医药用途
WO2022268152A1 (zh) 2021-06-24 2022-12-29 杭州中美华东制药有限公司 Glp-1受体激动剂及其组合物和用途
CN115521320B (zh) * 2021-06-25 2023-09-05 沈阳兴齐眼药股份有限公司 一种制备普拉洛芬的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6345270A (ja) * 1986-02-11 1988-02-26 Takeda Chem Ind Ltd １，４−ベンゾオキサジン誘導体，その製造法およびそれを含有する医薬用組成物
EP0233728A1 (en) * 1986-02-11 1987-08-26 Takeda Chemical Industries, Ltd. 1,4-Benzoxazine derivatives their production and use
CA2233888A1 (en) * 1995-10-06 1997-04-10 Ligand Pharmaceuticals Incorporated Dimer-selective rxr modulators and methods for their use
WO2000042026A1 (en) * 1999-01-15 2000-07-20 Novo Nordisk A/S Non-peptide glp-1 agonists
CA2393265A1 (en) * 1999-12-03 2001-06-07 Kyoto Pharmaceutical Industries, Ltd. Novel heterocyclic compounds and salts thereof and medicinal use of the same
EP1125925A1 (en) * 2000-02-15 2001-08-22 Applied Research Systems ARS Holding N.V. Amine derivatives for the treatment of apoptosis
US20050222036A1 (en) 2000-08-24 2005-10-06 Thomas Jefferson University Peptide compositions with effects on blood glucose
KR20050114242A (ko) * 2003-03-26 2005-12-05 액테리온 파마슈티칼 리미티드 오렉신 수용체 길항제로서 이용되는테트라하이드로이소퀴놀릴 아세트아마이드 유도체
EA018225B1 (ru) * 2008-03-07 2013-06-28 Транстек Фарма, Инк. Соединения оксадиазоантрацена для лечения диабета
WO2011156655A2 (en) 2010-06-09 2011-12-15 Receptos, Inc. Novel glp-1 receptor stabilizers and modulators

Also Published As

Publication number Publication date
CN101959405A (zh) 2011-01-26
BRPI0910282A2 (pt) 2015-09-01
US20100197677A1 (en) 2010-08-05
US7906507B2 (en) 2011-03-15
CN101959405B (zh) 2014-07-02
US7727983B2 (en) 2010-06-01
IL207570A0 (en) 2010-12-30
US20100324033A1 (en) 2010-12-23
EA201071045A1 (ru) 2011-02-28
US20090306063A1 (en) 2009-12-10
IL207570A (en) 2014-03-31
MA32175B1 (fr) 2011-03-01
US20140187769A1 (en) 2014-07-03
AU2009221722A1 (en) 2009-09-11
US7790714B2 (en) 2010-09-07
US8933222B2 (en) 2015-01-13
KR20100131455A (ko) 2010-12-15
US8524708B2 (en) 2013-09-03
EP2262364B1 (en) 2016-03-02
US20130317015A1 (en) 2013-11-28
EA018225B1 (ru) 2013-06-28
AU2009221722B2 (en) 2014-12-18
CA2716664A1 (en) 2009-09-11
EP2262364A4 (en) 2012-04-04
HK1148435A1 (en) 2011-09-09
EP2262364A2 (en) 2010-12-22
US20110039837A1 (en) 2011-02-17
US20150087640A1 (en) 2015-03-26
JP2011513431A (ja) 2011-04-28
WO2009111700A2 (en) 2009-09-11
MX2010009752A (es) 2010-09-30
JP5382952B2 (ja) 2014-01-08
KR101616737B1 (ko) 2016-05-02
US9120813B2 (en) 2015-09-01
ZA201006367B (en) 2011-05-25
NZ587343A (en) 2012-05-25
CA2716664C (en) 2016-10-11
ES2567451T3 (es) 2016-04-22
US8703766B2 (en) 2014-04-22
WO2009111700A3 (en) 2010-03-04

Similar Documents

Publication Publication Date Title
DK2262364T3 (da) Oxadiazoanthracenforbindelser til behandling af diabetes
JP5755217B2 (ja) 置換アゾアントラセン誘導体、その医薬組成物とその使用の方法
KR20120103694A (ko) 아미노 옥사진 유도체